- Home
- RAAQ vs SGMT Comparison
RAAQ vs SGMT Comparison
Compare RAAQ & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RAAQ | SGMT |
|---|---|---|
| Founded | 2024 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.3M | 204.2M |
| IPO Year | 2025 | 2023 |
Fundamental Metrics
Financial Performance| Metric | RAAQ | SGMT |
|---|---|---|
| Price | $10.27 | $5.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 46.8K | ★ 882.2K |
| Earning Date | 01-01-0001 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.62 | $1.73 |
| 52 Week High | $10.83 | $11.41 |
Technical Indicators
Market Signals| Indicator | RAAQ | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.17 |
| Support Level | N/A | $5.39 |
| Resistance Level | N/A | $7.20 |
| Average True Range (ATR) | 0.00 | 0.49 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 29.02 |
Price Performance
Historical ComparisonAbout RAAQ Real Asset Acquisition Corp. Class A Ordinary Share
Real Asset Acquisition Corp is a blank check company.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.